Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -49.88% | -9.80% | 32.13% | 103.30% | 1,275.69% |
| Total Depreciation and Amortization | 23.26% | 14.79% | 5.75% | -2.29% | -3.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 148.89% | 128.68% | 114.60% | 380.26% | -123.16% |
| Change in Net Operating Assets | -1,669.21% | -407.29% | -349.24% | -364.71% | 116.75% |
| Cash from Operations | -77.20% | -71.95% | -77.52% | 11.52% | 412.77% |
| Capital Expenditure | -16.54% | 0.72% | -108.44% | -79.14% | -126.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 2,023.08% | 2,056.42% | 3,820.15% | -104.20% | -173.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 83.33% | 50.00% | 18.18% | -9.09% | -20.00% |
| Issuance of Common Stock | -92.48% | -93.43% | -50.35% | 33.39% | 558.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -92.45% | -92.45% | -129.79% | -28.85% | 38.37% |
| Cash from Financing | -143.40% | -140.49% | -82.08% | 28.81% | 595.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -83.64% | -80.77% | -61.02% | 16.11% | 466.97% |